Gamma-glutamyl transpeptidase is a promising biological marker of heart failure

Introduction. Currently, the search and study of new biological markers that can help early diagnosis of heart failure, serve as a laboratory tool for assessing the effectiveness of therapy, be a predictive marker of possible adverse clinical outcomes and a significant criterion for risk stratification is very relevant. While cardiospecific markers, including natriuretic peptides, their precursors, and highly sensitive troponins, are widely used in clinical practice, the need to use other markers does not have sufficient evidence. aspect of a biological marker of heart failure.

Gamma-glutamyl transpeptidase is an enzyme localized on the outer side of cell membranes and involved in the metabolism of glutathione and cysteine. This enzyme is a dimeric glycoprotein (68 kDa), consisting of 2 subunits – a large and a small (46 and 22 kDa). Gamma-glutamyl transpeptidase is encoded by a multigene family consisting of at least 7 different genes located on chromosome 22; however, only 1 of these genes is involved in the formation of a functional enzyme. Gamma-glutamyl transpeptidase was found in all cells except erythrocytes. There is a significant variability in enzyme activity, which is especially high in tissues with a secretory and absorptive function, such as the kidneys, biliary tract, intestines, and epididymis.

Purpose of the review is to present an overview of current publications devoted to the study of γ-glutamyl transpeptidase in the aspect of a biological marker of heart failure.

Materials and methods. The analysis of literature sources (foreign and domestic articles) was carried out in the databases: PubMed, RSCI, MedLine, Google Scholar, Science Direct. The search was performed according to the following keywords: biological markers, heart failure, γ-glutamyl transpeptidase, biological markers, heart failure, γ-glutamyl transpeptidase.

Results. In addition to its clinical use as a test for liver disease, biliary tract disease, and alcohol abuse, γ-glutamyl transpeptidase is of great interest because of its association with cardiovascular disease, diabetes, metabolic syndrome, and cancer. In the literature available to us, we found a small number of works devoted to the study of γ-glutamyl transpeptidase in patients with heart failure. In the review, we have presented data from experimental and clinical studies indicating a clear link between γ-glutamyl transpeptidase and heart failure. The pathogenetic mechanism of the possible relationship between γ-glutamyl transpeptidase and heart failure is not completely clear. The localization of this enzyme in tissues with a transport function has led to the assumption that it is involved in the transport of amino acids through the γ-glutamyl cycle.

Conclusion. Further deeper understanding of the structure and function of the enzyme is needed, as well as future clinical studies to determine the diagnostic, prognostic and possibly therapeutic significance of this biological marker.

1. Alieva A.M., Reznik E.V., Hasanova E.T. et al. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine 2018;8(5): 333–45. (In Russ.). DOI: 10.20514/2226-6704-2018-8-5-333-345.

2. Aliyeva A.M., Baykova I.E., Kislyakov V.A. et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Terapevticheskiy arkhiv = Therapeutic Archive 2019;91(9):145–9. (In Russ.). DOI: 10.26442/00403660.2019.09.000226.

3. Alieva A.M., Pinchuk T.V., Almazova I.I. et al. Сlinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum 2021;23(6):522–6. (In Russ.). DOI: 10.26442/20751753.2021.6.200606.

4. Castellano I., Merlino A. γ-Glutamyltranspeptidases: sequence, structure, biochemical properties, and biotechnological applications. Cell Mol Life Sci 2012;69(20):3381–94. DOI: 10.1007/s00018-012-0988-3.

5. Castellano I., Merlino A. Gammaglutamyl transpeptidases: structure and function. Springer, Basel, 2013. 57 р. DOI: 10.1007/978-3-0348-0682-4.

6. Ndrepepa G., Kastrati A. Gammaglutamyl transferase and cardiovascular disease. Ann Transl Med 2016;4(24):481. DOI: 10.21037/atm.2016.12.27.

7. Kunutsor S.K. Gamma-glutamyltransferase-friend or foe within? Liver Int 2016;36(12):1723–34. PMID: 27512925. DOI: 10.1111/liv.13221.

8. Ristoff E., Larsson A. Patients with genetic defects in the gamma-glutamyl cycle. Chem Biol Interact 1998;(111, 112):113–21. PMID: 9679548. DOI: 10.1016/s0009-2797(97)00155-5.

9. Franzini M., Bramanti E., Ottaviano V. et al. A high-performance gel filtration chromatography method for γ-glutamyltransferase fraction analysis. Anal Biochem 2008;374(1):1–6. PMID: 18023410. DOI: 10.1016/j.ab.2007.10.025.

10. Fornaciari I., Fierabracci V., Corti A. et al. Gamma-glutamyltransferase fractions in human plasma and bile: characteristic and biogenesis. PLoS One 2014;9(2):e88532. PMID: 24533101. DOI: 10.1371/journal.pone.0088532.

11. Neuman M.G., Malnick S., Chertin L. Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome. J Pharm Pharm Sci 2020;23(1):65–74. PMID: 32310756. DOI: 10.18433/jpps30923.

12. van Deursen V.M., Damman K., Hillege H.L. et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16(1):84–90. PMID: 20123323. DOI: 10.1016/j.cardfail.2009.08.002.

13. Poelzl G., Eberl C., Achrainer H. et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009;2(4):294–302. PMID: 19808352. DOI: 10.1161/CIRCHEARTFAILURE.108.826735.

14. Poelzl G., Michael E., von der Heidt A. et al. Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance Eur J Intern Med 2013;24(2):177–82. PMID: 23266236. DOI: 10.1016/j.ejim.2012.11.009.

15. Turfan M., Tasal A., Erdogan E. et al. Serum gamma-glutamyl transferase levels and in-hospital mortality in patients with acute heart failure. Kardiol Pol 2014;72(8):735–9. PMID: 24526562. DOI: 10.5603/KP.a2014.0048.

16. Sarikaya S., Aydin G., Yucel H. et al. Usefulness of admission gammaglutamyltransferase level for predicting new-onset heart failure in patients with acute coronary syndrome with left ventricular systolic dysfunction. Turk Kardiyol Dern Ars 2014;42(3):236–44. PMID: 24769815. DOI: 10.5543/tkda.2014.27547.

17. Kunutsor S.K., Laukkanen J.A., Bluemke D.A. et al. Baseline and longterm gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middleaged Finnish men: Prospective study and pooled analysis of published evidence. Eur J Prev Cardiol 2016;23(13):1354–62. PMID: 27084895. DOI: 10.1177/2047487316644086.

18. Sudharshana Murthy K.A., Ashoka H.G., Aparna A.N. Evaluation and comparison of biomarkers in heart failure. Indian Heart J 2016;68(1):S22–8. PMID: 27056649. DOI: 10.1016/j.ihj.2015.09.003.

19. Zheng Y.Y., Wu T.T., Chen Y. et al. Moderate serum γ-glutamyl transferase level is beneficial for heart failure after percutaneous coronary intervention. Metab Syndr Relat Disord 2019;17(5):266–71. PMID: 30990355. DOI: 10.1089/met.2019.0009.

20. Koyama T., Tsubota A., Sawano T. et al. Involvement of γ-Glutamyl Transpeptidase in Ischemia/Reperfusion-Induced Cardiac Dysfunction in Isolated Rat Hearts. Biol Pharm Bull 2019;42(11):1947–52. PMID: 31685777. DOI: 10.1248/bpb.b19-00434.

21. Cho E.J., Han K., Lee S.P. et al. Liver enzyme variability and risk of heart disease and mortality: A nationwide populationbased study. Liver Int 2020;40(6):1292–302. PMID: 32153096. DOI: 10.1111/liv.14432.

22. Kubala M., Hermida A., Buiciuc O. et al. Effect of serum γ-glutamyltranferase and albumin levels on the response to cardiac resynchronization therapy in the elderly. J Geriatr Cardiol 2020;17(6):313–20. PMID: 32670361. DOI: 10.11909/j.issn.1671-5411.2020.06.003.

23. Bogaert J., Symons R., Rafouli-Stergiou P. et al. Assessment of right-sided heart failure in patients with dilated cardiomyopathy using magnetic resonance relaxometry of the liver. Am J Cardiol 2021;149:103–11. PMID: 33762175. DOI: 10.1016/j.amjcard.2021.03.012.

24. Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia = Cardiology 2020;60(4):101–8. (In Russ.). PMID: 32394864. DOI: 10.18087/cardio.2020.4.n487.

25. Vasan R.S. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006;113(19):2335–62. PMID: 16702488. DOI: 10.1161/CIRCULATIONAHA.104.482570.

26. Mason J.E., Starke R.D., van Kirk J.E. Gamma-glutamyl transferase: A novel cardiovascular risk biomarker. Prev Cardiol 2010;13(1):36–41. PMID: 20021625. DOI: 10.1111/j.1751-7141.2009.00054.x.

27. Kunutsor S.K., Bakker S.J.L., KootstraRos J.E. et al. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 2015;238(2):356–64. PMID: 25555268. DOI: 10.1016/j.atherosclerosis.2014.12.045.

28. Ndrepepa G., Braun S., Schunkert H. et al. Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. Clin Chim Acta 2016;452:155–60. DOI: 10.1016/j.cca.2015.11.013.

29. Kengne A.P., Czernichow S., Stamatakis E. et al. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: Pooling of three British Health Surveys. J Hepatol 2012;57(5):1083–9. PMID: 22796154. DOI: 10.1016/j.jhep.2012.06.034.